Epoch Biodesign expands to MAYDE
Kadans Science Partner (“Kadans”) has today announced Epoch Biodesign, an innovative biorecycling platform, as one of the early occupiers at its recently completed lab and research facility, Mayde, in Tileyard Quarter, King’s Cross, London.
Epoch Biodesign, which earlier this month announced the closing of an oversubscribed $18.3m Series A round to scale their breakthrough enzymatic recycling technology, is expanding its London presence, taking new office and lab space that will allow the company to expand its chemistry lab capacity.
Epoch Biodesign is emerging as a pioneer in the field of engineered biology, aiming to transform the way plastic waste is managed and utilised. Through innovative enzyme engineering, the company has developed game-changing solutions that tackle the root cause of plastic pollution. They have built a set of economical, scalable recycling routes for complex waste that currently have no end-of-life solution, paving the way for a more sustainable future and avoiding landfill and incineration.
The new state-of-the-art, purpose-built 114,000 sq ft laboratory and office building is located in King’s Cross’ growing community of life science and tech business. Officially opened in November 2024, Mayde is the first of four Kadans projects to be based at Tileyard Quarter.
The building is the first and only commercially facing combined GMP manufacturing, laboratory and office facility in London, comprising of space capable for heavy chemistry use as well as all areas of science, specifically designed to support expansion from research and development into commercialisation. It also includes an on-site barista bar, communal meeting rooms and other onsite amenities.
The building is designed to a lab first principle through all elements of design with a dedicated loading area and services within the building.
As well as benefitting from our wider, global ecosystem of occupiers and partners, clients at Mayde will also become part of the wider King’s Cross science cluster, gaining access to a network of like-minded scientific organisations, professionals and academics.
Jacob Nathan, Founder & CEO, Epoch Biodesign, said: “We’re excited to grow our facilities and footprint in London. Mayde provides an excellent space for us to expand our chemistry and mid-scale production capabilities.”
Katie Nelson, Head of Leasing UK & Ireland, Kadans Science Partner, added: “Kadans creates environments in which scientific organisations can thrive and Epoch Biodesign’s decision to take space at our Mayde facility is a great example of that happening in action. Mayde will provide Epoch with providing tailored space that can grow with them as their requirements evolve. With its comprehensive facilities and close proximity to other companies within King’s Cross’ life science cluster, we are excited to continue welcoming other leading biotech and life science companies to Mayde and allow us to become part of their growth journey within this thriving community.”
DTRE and Savills acted on behalf of Kadans Science Partner throughout the transaction.
